For survival, several clinical variables displayed significant differences in expired patients, including a higher median BMI (p = 0.040), positive BRCA1 gene mutation (p = 0.046), preoperative NAC treatment (p = 0.016), axillary lymph node dissection in the total mastectomy group (p = 0.044), less HRT (p = 0.018), with recurrence (p < 0.001), larger mean tumor size (p = 0.016), histologic grade of invasive cancer (p = 0.018), non-positive PR rate (p = 0.001), and high Ki-67 (p = 0.001). Here, BRCA1 is linked to neoplasm.